Industry Holds Breath As FDA Weighs Remicade Biosimilar
Celltrion Inc. said Monday it's seeking U.S. Food and Drug Administration approval of a biosimilar version of Johnson & Johnson's extremely complex blockbuster Remicade, starting a highly consequential review process that...To view the full article, register now.
Already a subscriber? Click here to view full article